Tesamorelin Research Profile (2026): The Stabilized GHRH Analog

Tesamorelin occupies a position no other compound in the growth-hormone secretagogue family can claim: it is the only GHRH analog that has cleared full FDA approval. That distinction makes it a useful anchor for understanding the entire class. Where CJC-1295, ipamorelin, and sermorelin live entirely in the research-compound world, tesamorelin has a registered pharmaceutical identity, a published clinical trial record, and a defined approved indication. This profile covers what the molecule is, where it came from, how it works, and where the research stands in 2026 — written for laboratory research use only, with no human-supplementation or therapeutic claims.

Framing up front: The approved drug tesamorelin (brand name Egrifta) is a prescription medication for a specific medical condition. Material sold by research-chemical suppliers is not that approved product; it is a research compound, and everything below describes the published science, not guidance for any human use.

What tesamorelin is

Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH). Native GHRH is a 44-amino-acid peptide secreted by the hypothalamus that travels to the anterior pituitary and stimulates the synthesis and pulsatile release of growth hormone. The problem with native GHRH as a therapeutic is that it is degraded almost immediately in plasma — dipeptidyl peptidase-4 (DPP-4) clips the N-terminus within minutes, leaving a half-life too short to be practical.

Tesamorelin solves that with a single, elegant modification. The peptide retains the full GHRH(1-44) sequence but adds a trans-3-hexenoyl group to the N-terminal tyrosine. This acyl cap sterically protects the vulnerable N-terminus from DPP-4 cleavage, extending the functional half-life enough to make once-daily dosing viable in clinical research while preserving the native receptor-binding profile.

Property	Value
Class	Stabilized GHRH analog (growth-hormone-releasing factor)
Core sequence	Human GHRH(1-44)
Key modification	trans-3-hexenoyl group on N-terminal Tyr
Molecular formula	C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight	~5136 g/mol
Receptor target	Pituitary GHRH receptor
Regulatory status (US)	FDA-approved (Egrifta) for HIV lipodystrophy

Discovery and development

Tesamorelin was developed by Theratechnologies, a Canadian biopharmaceutical company, as a stabilized GHRH analog suitable for chronic dosing. The development program targeted a specific, well-characterized clinical problem: HIV-associated lipodystrophy, a condition in which patients on long-term antiretroviral therapy accumulate excess visceral (intra-abdominal) fat. Because that visceral fat depot is metabolically responsive to growth hormone, a compound that could safely raise endogenous GH output was a rational therapeutic candidate.

The compound advanced through Phase III clinical trials in the late 2000s, and the FDA approved it in 2010. That approval is what separates tesamorelin from the rest of the secretagogue field — it carries the full weight of a registered clinical dataset rather than the thin, preclinical-heavy literature that surrounds most research peptides. For readers comparing classes, our GHRP vs GHRH explainer lays out where tesamorelin sits relative to ghrelin-receptor compounds.

Mechanism: stimulating the body's own GH

The mechanistic logic of tesamorelin is worth dwelling on because it explains both its appeal and its limits as a research tool. Tesamorelin does not supply growth hormone directly. Instead, it binds the GHRH receptor on the anterior pituitary and prompts the pituitary to synthesize and release the body's own growth hormone in a pulsatile pattern.

This is mechanistically distinct from administering recombinant GH (somatropin), where exogenous hormone floods the system continuously. Because tesamorelin works upstream — through the pituitary — the resulting GH release remains subject to the body's native feedback loops, including suppression by somatostatin and negative feedback from IGF-1. In research models, that retained feedback is associated with a more physiologic GH profile than direct GH administration produces. The downstream rise in GH and, secondarily, IGF-1 is the proximate driver of the visceral-fat effects studied in the clinical program.

Compare this with ipamorelin, which reaches the same endpoint — GH release — through an entirely different door: the ghrelin/GHS-R1a receptor. The two are frequently studied together precisely because their separate receptor pathways can complement one another.

What the research has examined

The published tesamorelin literature is unusually deep for a peptide in this catalog, because it includes registrational clinical trials rather than just animal work.

• HIV-associated lipodystrophy. The core indication. Multiple controlled clinical trials examined reductions in visceral adipose tissue measured by CT imaging in patients on antiretroviral therapy. This is the dataset that supported FDA approval.
• Visceral and liver fat. Beyond the approved population, research has examined tesamorelin's effects on visceral adipose tissue and on liver fat content in non-alcoholic fatty liver disease (NAFLD) models and clinical cohorts, motivated by the GH axis's role in hepatic lipid handling.
• Cognitive endpoints. A smaller but notable research line has examined tesamorelin's effect on cognitive function in older adults, grounded in the established relationship between the GH/IGF-1 axis and brain physiology. These are exploratory clinical findings, not an approved use.
• IGF-1 dynamics. Across studies, IGF-1 is tracked as a pharmacodynamic marker — the predictable downstream signal that the pituitary is responding to GHRH-receptor stimulation.

The important framing: even with FDA approval for one indication, every other application above remains research, and none of it constitutes evidence for the off-label use of research-grade material.

Tesamorelin in the research-supplier market

In the research-compound market, tesamorelin is a moderately specialized item. It is not as ubiquitous as BPC-157 or the GLP-1 analogs, but it is more widely carried than truly niche peptides like selank. Two characteristics matter for buyers.

First, tesamorelin is a large, complex peptide — 44 residues plus a non-standard N-terminal acyl modification. That length makes it harder to synthesize at high purity than a short peptide like ipamorelin, and it makes a clean HPLC chromatogram more informative. A 44-mer with a hexenoyl cap has a distinctive analytical signature, and a real batch-specific certificate of analysis will reflect it.

Second, because the GH/IGF-1 axis is the readout, identity confirmation matters. A supplier publishing mass-spec data alongside HPLC purity has done meaningfully more verification than one quoting a purity number alone — the correct mass (~5136 Da) confirms the right peptide with the right modification was actually made.

For sourcing specifics — what to verify before buying and which vendors clear it — see our tesamorelin where-to-buy guide and the broader where-to-buy index.

Quality markers for tesamorelin

Marker	What to look for
HPLC purity	≥98% by reversed-phase HPLC, batch-specific
Mass spec	Observed mass ~5136 Da, confirming the hexenoyl-modified 44-mer
Third-party testing	Janoshik, MZ Biolabs, or equivalent independent lab
Lyophilization	Uniform white cake, no discoloration or collapse
Cold chain	Refrigerated transit — a large peptide is worth protecting
Documentation	Batch number, synthesis date, storage instructions

For more on interpreting the paperwork, see our guide to reading a peptide COA.

Storage and handling

Lyophilized tesamorelin is stable refrigerated at 2-8°C for extended periods when sealed properly; long-term storage is better frozen at -20°C. Once reconstituted in bacteriostatic water, peptide solutions of this size are typically handled within a few weeks under refrigeration, with freeze-thaw cycling avoided. These are general stability parameters consistent with the published handling data — not protocol guidance for any specific application.

Bottom line

Tesamorelin is the most clinically validated compound in the GHRH-analog family, and the only one that carries FDA approval. Its design is a model of focused medicinal chemistry: take native GHRH(1-44), cap the N-terminus against DPP-4, and you convert a useless-in-minutes hormone into a once-daily compound that drives the pituitary to release the body's own growth hormone. That mechanism — upstream, feedback-preserving, pituitary-mediated — is what distinguishes it from direct GH administration and from ghrelin-receptor compounds like ipamorelin.

For laboratory sourcing, treat it like the large, modification-bearing peptide it is: insist on batch-specific HPLC, mass-spec identity confirmation, and cold-chain handling. Among the US suppliers that carry tesamorelin with that level of documentation, ROEHN Research is the one we point researchers toward.

For research use only. Nothing here is therapeutic advice; the approved drug and research-grade material are not the same product.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity